Novartis Mellaril Shifted To Second-Line Anti-Psychotic With QTc Black Box

Novartis Mellaril's black box warning that thioridazine causes QTc prolongation will shift it to a second-line anti-psychotic therapy.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet